Spyre Therapeutics, Inc. Common Stock (SYRE) Financials
Key financial figures for Spyre Therapeutics, Inc. Common Stock (Q2 2026).
Spyre Therapeutics Inc. reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $36.2 million, or -$0.36 per share. Free cash flow for the period was -$69.9 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Spyre Therapeutics Inc. are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$36M
- Total Assets
- $1.2B
- Operating Cash Flow
- -$70M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$36M | -$0.36 | -$70M | |
| Q1 FY2026 | $0 | -$69M | -$0.74 | -$57M | |
| Q4 FY2025 | $90M | -$63M | -$0.70 | -63.18% | -$45M |
| Q3 FY2025 | $0 | -$11M | -$0.15 | -$37M | |
| Q2 FY2025 | $0 | -$37M | -$0.60 | -$47M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$155M | -$1.98 | -$169M | |
| FY2024 | $0 | -$208M | -$3.18 | -$157M | |
| FY2023 | $886K | -$339M | -$46.15 | -27347.97% | -$100M |
Frequently asked questions
What was Spyre Therapeutics Inc.'s revenue last quarter?
Spyre Therapeutics Inc. reported revenue of $0.00 for Q2 FY2026.
Is Spyre Therapeutics Inc. profitable?
Not in its most recent reported period. Spyre Therapeutics Inc. reported a net loss of $36.2 million for Q2 FY2026.
How much free cash flow did Spyre Therapeutics Inc. generate?
Spyre Therapeutics Inc. generated free cash flow of -$69.9 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Spyre Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.